You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for METHYLPHENIDATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000268 ↗ Cocaine Abuse and Attention Deficit Disorder - 3 Completed New York State Psychiatric Institute N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 ↗ Cocaine Abuse and Attention Deficit Disorder - 3 Completed National Institute on Drug Abuse (NIDA) N/A 1995-05-01 The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00003266 ↗ Methylphenidate in Treating Patients With Melanoma Completed National Cancer Institute (NCI) Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00003266 ↗ Methylphenidate in Treating Patients With Melanoma Completed Eastern Cooperative Oncology Group Phase 3 1999-06-01 RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00012584 ↗ Treatment of Youth With ADHD and Anxiety Completed National Institute of Mental Health (NIMH) N/A 2000-11-01 The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for METHYLPHENIDATE

Condition Name

Condition Name for METHYLPHENIDATE
Intervention Trials
Attention Deficit Hyperactivity Disorder 100
Adhd 47
Attention Deficit Disorder With Hyperactivity 46
Healthy 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for METHYLPHENIDATE
Intervention Trials
Attention Deficit Disorder with Hyperactivity 216
Hyperkinesis 147
Disease 87
Fatigue 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for METHYLPHENIDATE

Trials by Country

Trials by Country for METHYLPHENIDATE
Location Trials
United States 630
Canada 42
Israel 26
Germany 21
France 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for METHYLPHENIDATE
Location Trials
California 46
Massachusetts 41
New York 41
Texas 41
Ohio 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for METHYLPHENIDATE

Clinical Trial Phase

Clinical Trial Phase for METHYLPHENIDATE
Clinical Trial Phase Trials
Phase 4 138
Phase 3 81
Phase 2/Phase 3 15
[disabled in preview] 68
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for METHYLPHENIDATE
Clinical Trial Phase Trials
Completed 261
Unknown status 45
Recruiting 36
[disabled in preview] 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for METHYLPHENIDATE

Sponsor Name

Sponsor Name for METHYLPHENIDATE
Sponsor Trials
National Institute of Mental Health (NIMH) 29
Massachusetts General Hospital 28
National Institute on Drug Abuse (NIDA) 19
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for METHYLPHENIDATE
Sponsor Trials
Other 447
Industry 136
NIH 80
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.